In a groundbreaking report, the World Health Organization (WHO) has declared that cannabidiol (CBD) — the relaxant property of cannabis used in medical marijuana — is beneficial for cancer, epilepsy, Alzheimer’s, Parkinson’s and many more diseases, AND should not be a scheduled drug.

According to the U.S. federal law, marijuana is classified as a Schedule I drug with “no currently accepted medical use and a high potential for abuse” alongside heroin, LSD, ecstasy, methaqualone, and peyote.

But WHO’s Expert Committee on Drug Dependence [ECDD] gathered scientific evidence on therapeutic use and side effects of cannabis and cannabis components, and confirmed:

“Recent evidence from animal and human studies shows that its use could have some therapeutic value for seizures due to epilepsy and related conditions. Current evidence also shows that cannabidiol is not likely to be abused or create dependence as for other cannabinoids (such as Tetra Hydro Cannabinol (THC), for instance).

“The ECDD therefore concluded that current information does not justify scheduling of cannabidiol and postponed a fuller review of cannabidiol preparations to May 2018, when the committee will undertake a comprehensive review of cannabis and cannabis related substances.”

WHO experts also recommended imposing stronger restrictions on fentanyl, a powerful synthetic opioid analgesic that is similar to morphine but is 50 to 100 times more potent and has taken thousands of lives in the U.S. drug addiction epidemic.

Read More...